Phase	phase	O	O
I	i	O	O
trial	trial	O	O
of	of	O	O
13-cis-retinoic	13-cis-retinoic	O	O
acid	acid	S_chemicals	O
in	in	O	O
children	children	O	O
with	with	O	O
neuroblastoma	neuroblastoma	O	S_disease
following	following	O	O
bone	bone	O	B_disease
marrow	marrow	O	I_disease
transplantation	transplantation	O	O
.	.	O	O

PURPOSE	purpose	O	O
:	:	O	O
Treatment	treatment	O	O
of	of	O	O
neuroblastoma	neuroblastoma	O	S_disease
cell	cell	O	O
lines	lines	O	O
with	with	O	O
13-cis-retinoic	13-cis-retinoic	O	O
acid	acid	S_chemicals	O
(	(	O	O
cis-RA	cis-ra	O	O
)	)	O	O
can	can	O	O
cause	cause	O	O
sustained	sustained	O	O
inhibition	inhibition	O	O
of	of	O	O
proliferation	proliferation	O	O
.	.	O	O

Since	since	O	O
cis-RA	cis-ra	O	O
has	has	O	O
demonstrated	demonstrated	O	O
clinical	clinical	O	O
responses	responses	O	O
in	in	O	O
neuroblastoma	neuroblastoma	O	S_disease
patients	patients	O	O
,	,	O	O
it	it	O	O
may	may	O	O
be	be	O	O
effective	effective	O	O
in	in	O	O
preventing	preventing	O	O
relapse	relapse	O	S_disease
after	after	O	O
cytotoxic	cytotoxic	O	O
therapy	therapy	O	O
.	.	O	O

This	this	O	O
phase	phase	O	O
I	i	O	O
trial	trial	O	O
was	was	O	O
designed	designed	O	O
to	to	O	O
determine	determine	O	O
the	the	O	O
maximal-tolerated	maximal-tolerated	O	O
dosage	dosage	O	O
(	(	O	O
MTD	mtd	O	O
)	)	O	O
,	,	O	O
toxicities	toxicities	O	O
,	,	O	O
and	and	O	O
pharmacokinetics	pharmacokinetics	O	O
of	of	O	O
cis-RA	cis-ra	O	O
administered	administered	O	O
on	on	O	O
an	an	O	O
intermittent	intermittent	O	O
schedule	schedule	O	O
in	in	O	O
children	children	O	O
with	with	O	O
neuroblastoma	neuroblastoma	O	S_disease
following	following	O	O
bone	bone	O	B_disease
marrow	marrow	O	I_disease
transplantation	transplantation	O	O
(	(	O	O
BMT	bmt	O	O
)	)	O	O
.	.	O	O

PATIENTS	patients	O	O
AND	and	O	O
METHODS	methods	O	O
:	:	O	O
Fifty-one	fifty-one	O	O
assessable	assessable	O	O
patients	patients	O	O
,	,	O	O
2	2	O	O
to	to	O	O
12	12	O	O
years	years	O	O
of	of	O	O
age	age	O	O
,	,	O	O
were	were	O	O
treated	treated	O	O
with	with	O	O
oral	oral	O	O
cis-RA	cis-ra	O	O
administered	administered	O	O
in	in	O	O
two	two	O	O
equally	equally	O	O
divided	divided	O	O
doses	doses	O	O
daily	daily	O	O
for	for	O	O
2	2	O	O
weeks	weeks	O	O
,	,	O	O
followed	followed	O	O
by	by	O	O
a	a	O	O
2-week	2-week	O	O
rest	rest	O	O
period	period	O	O
,	,	O	O
for	for	O	O
up	up	O	O
to	to	O	O
12	12	O	O
courses	courses	O	O
.	.	O	O

The	the	O	O
dose	dose	O	O
was	was	O	O
escalated	escalated	O	O
from	from	O	O
100	100	O	O
to	to	O	O
200	200	O	O
mg/m2/d	mg/m2/d	O	O
until	until	O	O
dose-limiting	dose-limiting	O	O
toxicity	toxicity	O	O
(	(	O	O
DLT	dlt	O	O
)	)	O	O
was	was	O	O
observed	observed	O	O
.	.	O	O

A	a	O	O
single	single	O	O
intrapatient	intrapatient	O	O
dose	dose	O	O
escalation	escalation	O	O
was	was	O	O
permitted	permitted	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
The	the	O	O
MTD	mtd	O	O
of	of	O	O
cis-RA	cis-ra	O	O
was	was	O	O
160	160	O	O
mg/m2/d	mg/m2/d	O	O
.	.	O	O

Dose-limiting	dose-limiting	O	O
toxicities	toxicities	O	O
in	in	O	O
six	six	O	O
of	of	O	O
nine	nine	O	O
patients	patients	O	O
at	at	O	O
200	200	O	O
mg/m2/d	mg/m2/d	O	O
included	included	O	O
hypercalcemia	hypercalcemia	O	S_disease
(	(	O	O
n	n	O	O
=	=	O	O
3	3	O	O
)	)	O	O
,	,	O	O
rash	rash	O	S_disease
(	(	O	O
n	n	O	O
=	=	O	O
2	2	O	O
)	)	O	O
,	,	O	O
and	and	O	O
anemia/thrombocytopenia/emesis/rash	anemia/thrombocytopenia/emesis/rash	O	O
(	(	O	O
n	n	O	O
=	=	O	O
1	1	O	O
)	)	O	O
.	.	O	O

All	all	O	O
toxicities	toxicities	O	O
resolved	resolved	O	O
after	after	O	O
cis-RA	cis-ra	O	O
was	was	O	O
discontinued	discontinued	O	O
.	.	O	O

Three	three	O	O
complete	complete	O	O
responses	responses	O	O
were	were	O	O
observed	observed	O	O
in	in	O	O
marrow	marrow	O	O
metastases	metastases	O	S_disease
.	.	O	O

Serum	serum	O	O
levels	levels	O	O
of	of	O	O
7.4	7.4	O	O
+	+	O	O
/-	/-	O	O
3.0	3.0	O	O
mumol/L	mumol/l	O	O
(	(	O	O
peak	peak	O	O
)	)	O	O
and	and	O	O
4.0	4.0	O	O
+	+	O	O
/-	/-	O	O
2.8	2.8	O	O
mumol/L	mumol/l	O	O
(	(	O	O
trough	trough	O	O
)	)	O	O
at	at	O	O
the	the	O	O
MTD	mtd	O	O
were	were	O	O
maintained	maintained	O	O
during	during	O	O
14	14	O	O
days	days	O	O
of	of	O	O
therapy	therapy	O	O
.	.	O	O

The	the	O	O
DLT	dlt	O	O
correlated	correlated	O	O
with	with	O	O
serum	serum	O	O
levels	levels	O	O
>	>	O	O
or	or	O	O
=	=	O	O
10	10	O	O
mumol/L.	mumol/l.	O	O
CONCLUSION	conclusion	O	O
:	:	O	O
The	the	O	O
MTD	mtd	O	O
of	of	O	O
cis-RA	cis-ra	O	O
given	given	O	O
on	on	O	O
this	this	O	O
intermittent	intermittent	O	O
schedule	schedule	O	O
was	was	O	O
160	160	O	O
mg/m2/d	mg/m2/d	O	O
.	.	O	O

Serum	serum	O	O
levels	levels	O	O
known	known	O	O
to	to	O	O
be	be	O	O
effective	effective	O	O
against	against	O	O
neuroblastoma	neuroblastoma	O	S_disease
in	in	O	O
vitro	vitro	O	O
were	were	O	O
achieved	achieved	O	O
at	at	O	O
this	this	O	O
dose	dose	O	O
.	.	O	O

The	the	O	O
DLT	dlt	O	O
included	included	O	O
hypercalcemia	hypercalcemia	O	S_disease
,	,	O	O
and	and	O	O
may	may	O	O
be	be	O	O
predicted	predicted	O	O
by	by	O	O
serum	serum	O	O
cis-RA	cis-ra	O	O
levels	levels	O	O
.	.	O	O

Monitoring	monitoring	O	O
of	of	O	O
serum	serum	O	O
calcium	calcium	S_chemicals	O
and	and	O	O
cis-RA	cis-ra	O	O
levels	levels	O	O
is	is	O	O
indicated	indicated	O	O
in	in	O	O
future	future	O	O
trials	trials	O	O
.	.	O	O

